In a post in USAID’s “IMPACTblog,” Susan Moffson, senior program officer of the agency’s Maternal and Child Health Integrated Program (MCHIP) program, examines a partnership with the Directorate of Health Services in Jharkhand state in India “to pilot an innovative approach for estimating the number of women who use a uterotonic drug after birth to protect them from [postpartum hemorrhage (PPH)].” She writes, “USAID/MCHIP’s innovative estimation tool makes it possible to build an accurate picture of whether a country is doing everything it should to stop women from dying of this preventable condition. … Such programs would ensure that oxytocin is available to women who give birth with trained health care workers, and that misoprostol is available to women who give birth at home. These combined efforts could save the lives of countless women, no matter where they give birth” (10/29).